Auriga Reiterates Buy on MedAssets

Auriga is out with its report today on MedAssets MDAS, reiterating Buy. In its report, Auriga writes, "In our view, MDAS' narrowed EPS range of $0.96-$1.02 on albeit a slightly weaker revenue guide is impressive enough to offset the tremendous negative sentiment heading into earnings. We find the stock very attractively valued and recommend purchase at current levels." Auriga maintains a $21 PT on MDAS. Shares of MDAS closed Monday at $12.00.